Dose Effect Evaluation and Therapeutic Window of the Neuro-EPO Nasal Application for the Treatment of the Focal Ischemia Model in the Mongolian Gerbil
Cerebrovascular disease is the third leading cause of death and the leading cause of disability in Cuba and in several developed countries. A possible neuroprotective agent is the rHu-EPO, whose effects have been demonstrated in models of brain ischemia. The Neuro-EPO is a derivative of the rHu-EPO...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/607498 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567197041426432 |
|---|---|
| author | Iliana Sosa Teste Yuneidys Mengana Tamos Yamila Rodríguez Cruz Adriana Muñoz Cernada Janette Cruz Rodríguez Nelvis Subirós Martínez Rosa Maria Coro Antich Alina González-Quevedo Julio Cesar García Rodríguez |
| author_facet | Iliana Sosa Teste Yuneidys Mengana Tamos Yamila Rodríguez Cruz Adriana Muñoz Cernada Janette Cruz Rodríguez Nelvis Subirós Martínez Rosa Maria Coro Antich Alina González-Quevedo Julio Cesar García Rodríguez |
| author_sort | Iliana Sosa Teste |
| collection | DOAJ |
| description | Cerebrovascular disease is the third leading cause of death and the leading cause of disability in Cuba and in several developed countries. A possible neuroprotective agent is the rHu-EPO, whose effects have been demonstrated in models of brain ischemia. The Neuro-EPO is a derivative of the rHu-EPO that avoids the stimulation of erythropoiesis. The aim of this study was to determine the Neuro-EPO delivery into the central nervous system (CNS) to exert a neuroprotective effect in cerebral ischemia model of the Mongolian gerbil. The Neuro-EPO in a rate of 249.4 UI every 8 hours for 4 days showed 25% higher viability efficacy (𝑃>0.01), improving neurological score and behavior of the spontaneous exploratory activity, the preservation of CA3 areas of the hippocampus, the cortex, and thalamic nuclei in the focal ischemia model of the Mongolian gerbil. In summary, this study, the average dose-used Neuro-EPO (249.4 UI/10 μL/every 8 hours for 4 days), proved to be valid indicators of viability, neurological status, and spontaneous exploratory activity, being significantly lower than that reported for the systemically use of the rHu-EPO as a neuroprotectant. Indeed, up to 12 h after brain ischemia is very positive Neuro-EPO administration by the nasal route as a candidate for neuroprotection. |
| format | Article |
| id | doaj-art-cedc6f5553ad42d5b6d240979bae489e |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-cedc6f5553ad42d5b6d240979bae489e2025-02-03T01:02:15ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/607498607498Dose Effect Evaluation and Therapeutic Window of the Neuro-EPO Nasal Application for the Treatment of the Focal Ischemia Model in the Mongolian GerbilIliana Sosa Teste0Yuneidys Mengana Tamos1Yamila Rodríguez Cruz2Adriana Muñoz Cernada3Janette Cruz Rodríguez4Nelvis Subirós Martínez5Rosa Maria Coro Antich6Alina González-Quevedo7Julio Cesar García Rodríguez8National Center for Laboratory Animal Breeding, Havana, CubaNational Center for Laboratory Animal Breeding, Havana, CubaHistology Department, Preclinical and Basic Science Institute, Havana, CubaCenter of Molecular Immunology (CIM), Havana, CubaCenter of Research and Development of Medicaments (CIDEM), Havana, CubaInstitute of Neurology and Neurosurgery (INN), Havana, CubaInstitute of Neurology and Neurosurgery (INN), Havana, CubaInstitute of Neurology and Neurosurgery (INN), Havana, CubaNational Center for Laboratory Animal Breeding, Havana, CubaCerebrovascular disease is the third leading cause of death and the leading cause of disability in Cuba and in several developed countries. A possible neuroprotective agent is the rHu-EPO, whose effects have been demonstrated in models of brain ischemia. The Neuro-EPO is a derivative of the rHu-EPO that avoids the stimulation of erythropoiesis. The aim of this study was to determine the Neuro-EPO delivery into the central nervous system (CNS) to exert a neuroprotective effect in cerebral ischemia model of the Mongolian gerbil. The Neuro-EPO in a rate of 249.4 UI every 8 hours for 4 days showed 25% higher viability efficacy (𝑃>0.01), improving neurological score and behavior of the spontaneous exploratory activity, the preservation of CA3 areas of the hippocampus, the cortex, and thalamic nuclei in the focal ischemia model of the Mongolian gerbil. In summary, this study, the average dose-used Neuro-EPO (249.4 UI/10 μL/every 8 hours for 4 days), proved to be valid indicators of viability, neurological status, and spontaneous exploratory activity, being significantly lower than that reported for the systemically use of the rHu-EPO as a neuroprotectant. Indeed, up to 12 h after brain ischemia is very positive Neuro-EPO administration by the nasal route as a candidate for neuroprotection.http://dx.doi.org/10.1100/2012/607498 |
| spellingShingle | Iliana Sosa Teste Yuneidys Mengana Tamos Yamila Rodríguez Cruz Adriana Muñoz Cernada Janette Cruz Rodríguez Nelvis Subirós Martínez Rosa Maria Coro Antich Alina González-Quevedo Julio Cesar García Rodríguez Dose Effect Evaluation and Therapeutic Window of the Neuro-EPO Nasal Application for the Treatment of the Focal Ischemia Model in the Mongolian Gerbil The Scientific World Journal |
| title | Dose Effect Evaluation and Therapeutic Window of the Neuro-EPO Nasal Application for the Treatment of the Focal Ischemia Model in the Mongolian Gerbil |
| title_full | Dose Effect Evaluation and Therapeutic Window of the Neuro-EPO Nasal Application for the Treatment of the Focal Ischemia Model in the Mongolian Gerbil |
| title_fullStr | Dose Effect Evaluation and Therapeutic Window of the Neuro-EPO Nasal Application for the Treatment of the Focal Ischemia Model in the Mongolian Gerbil |
| title_full_unstemmed | Dose Effect Evaluation and Therapeutic Window of the Neuro-EPO Nasal Application for the Treatment of the Focal Ischemia Model in the Mongolian Gerbil |
| title_short | Dose Effect Evaluation and Therapeutic Window of the Neuro-EPO Nasal Application for the Treatment of the Focal Ischemia Model in the Mongolian Gerbil |
| title_sort | dose effect evaluation and therapeutic window of the neuro epo nasal application for the treatment of the focal ischemia model in the mongolian gerbil |
| url | http://dx.doi.org/10.1100/2012/607498 |
| work_keys_str_mv | AT ilianasosateste doseeffectevaluationandtherapeuticwindowoftheneuroeponasalapplicationforthetreatmentofthefocalischemiamodelinthemongoliangerbil AT yuneidysmenganatamos doseeffectevaluationandtherapeuticwindowoftheneuroeponasalapplicationforthetreatmentofthefocalischemiamodelinthemongoliangerbil AT yamilarodriguezcruz doseeffectevaluationandtherapeuticwindowoftheneuroeponasalapplicationforthetreatmentofthefocalischemiamodelinthemongoliangerbil AT adrianamunozcernada doseeffectevaluationandtherapeuticwindowoftheneuroeponasalapplicationforthetreatmentofthefocalischemiamodelinthemongoliangerbil AT janettecruzrodriguez doseeffectevaluationandtherapeuticwindowoftheneuroeponasalapplicationforthetreatmentofthefocalischemiamodelinthemongoliangerbil AT nelvissubirosmartinez doseeffectevaluationandtherapeuticwindowoftheneuroeponasalapplicationforthetreatmentofthefocalischemiamodelinthemongoliangerbil AT rosamariacoroantich doseeffectevaluationandtherapeuticwindowoftheneuroeponasalapplicationforthetreatmentofthefocalischemiamodelinthemongoliangerbil AT alinagonzalezquevedo doseeffectevaluationandtherapeuticwindowoftheneuroeponasalapplicationforthetreatmentofthefocalischemiamodelinthemongoliangerbil AT juliocesargarciarodriguez doseeffectevaluationandtherapeuticwindowoftheneuroeponasalapplicationforthetreatmentofthefocalischemiamodelinthemongoliangerbil |